Related Experiment Video

Updated: Aug 21, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Beyond β-Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology

C Reid Dotson1, Lilly Underwood1, Priscila Y Sato1

  • 1Division of Cardiovascular Disease, Department of Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.

Kinases and Phosphatases
|August 19, 2026
PubMed

Insights

G-protein-coupled receptor kinase 2 (GRK2) regulates heart function by braking beta-adrenergic receptors (βARs). Emerging evidence reveals GRK2’s noncanonical roles in cell signaling, offering new therapeutic targets for heart failure and cardio-oncology.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Pharmacology

Background:

  • Heart failure (HF) involves neurohormonal stress, myocardial remodeling, and inflammation.
  • Beta-adrenergic receptors (βARs) mediate cardiac chronotropic and inotropic responses, regulated by G-protein-coupled receptor kinase 2 (GRK2).
  • GRK2 traditionally acts as a brake on βARs and other G-protein-coupled receptor (GPCR) signaling.

Purpose of the Study:

  • To review recent advances in understanding the cell-specific functions of GRK2.
  • To explore the emerging biological roles of GRK2 in cardiac diseases.
  • To highlight opportunities for advancing mechanistic insights in cardio-oncology through GRK2 research.

Main Methods:

  • Literature review of existing studies on GRK2.
  • Analysis of evidence on GRK2's canonical and noncanonical functions.
  • Exploration of GRK2's role in cardiac pathophysiology and cardio-oncology.

Main Results:

  • GRK2 exhibits compartment- and cell-dependent functions beyond GPCR regulation.
  • Noncanonical GRK2 activities include metabolic control, organelle integrity, and immune-vascular signaling.
  • GRK2 plays emerging roles in cardiac diseases and cardio-oncology.

Conclusions:

  • Understanding GRK2's noncanonical functions is crucial for its therapeutic application.
  • Therapeutic value of GRK2 depends on context-specific, cell-specific understanding.
  • GRK2 offers potential for novel therapeutic strategies in heart failure and cardio-oncology.
Keywords:
GRK2anthracyclinescardio-oncologyheart failureimmune checkpoint inhibitorsischemia/reperfusionβ-adrenergic receptors

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...